19 July 2017
Visiongain’ has launched a new pharma report Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018 – 2028 : Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs.
A specialist sector within the overall pharmaceutical industry, the ophthalmic drugs market is dominated by a relatively small number of companies. The market is relatively mature though with opportunities for growth in key therapeutic areas. Key patent expirations have affected revenues in this market in recent years, particularly in the glaucoma segment.
The lead analyst of the report commented “Considerable success in the ophthalmic pharmaceutical market is likely for therapies that will accommodate the large unmet need for pharmacological therapies for currently-untreated ophthalmic conditions. Certain conditions, where surgery is the only treatment, have an unmet patient need for pharmaceutical treatments.
However, to be commercially successful, new products must overcome significant hurdles. These include the challenge of demonstrating efficacy and safety during regulatory approval (especially for chronic diseases), achieving adequate reimbursement, and addressing the growing threat of generic competition.”
Leading companies featured in the report include Akorn, Alcon, Allergan, Bausch & Lomb, Bayer, Novartis, Pfizer, Regeneron, Roche, Santen, Senju, Valeant
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.